impact of exploratory analysis on drug approval joga gobburu pharmacometrics office clinical...
Post on 27-Mar-2015
241 Views
Preview:
TRANSCRIPT
Impact of Exploratory Analysis on Drug Approval
Joga Gobburu
Pharmacometrics
Office Clinical Pharmacology, CDER, FDA
jogarao.gobburu@fda.hhs.gov
2
Take Home Message• Exploratory (e.g., pharmacometric) analyses
are often used to make regulatory decisions– Decisions are not entirely driven by the pre-specified
statistical analysis
• Need for change– Integrate strengths of both approaches
• Think “How exploratory analyses can help drug development?”
– Opportunities for collaboration between pharmacometricians and statisticians are abundant
• Think about “How can I facilitate this collaboration?”
3
Pharmacometrics (or Quantitative Experimental Medicine?)
• Science that deals with quantifying disease and pharmacology
• Applications– Benefit/Risk, dose individualization, trial design
• Diverse expertise– Clinical pharmacologists, Pharmacometricians,
Clinicians, Statisticians, Bioengineers
• Tools– Linear/Nonlinear Mixed effects models, Longitudinal
data analysis, Biological models, Stochastic simulations
4
Impact of Exploratory Analyses 2000-2004
Bhattaram et al. AAPS Journal. 2005; 7(3): Article 51. DOI: 10.1208/aapsj070351
Impact Approval Labeling
Pivotal 54% 57%
Supportive 46% 30%
No Contribution 0 14%
Pivotal: Regulatory decision will not be the same without PM reviewSupportive: Regulatory decision is supported by PM review
5
Pivotal: Regulatory decision will not be the same without PM reviewSupportive: Regulatory decision is supported by PM review
Impact →Discipline
Approval Labeling
PM Reviewer 95% 100%
DCP Reviewer 95% 100%
DCP TL 90% 94%
Medical Reviewer 90%@ 90%@
DCP=Division of Clinical Pharmacology@=survey pending in 1 case
Impact of Exploratory Analyses 2005-2006
6
NDA Case Study• Drug is proposed for a ‘rare’ debilitating,
fatal disease with no approved treatment.• One trial successful and other failed
– Failure likely due to trial execution errors• Potential miscommunication about dose timing
– Primary variable: Change in symptom score
• Key question– Is there adequate evidence for the
effectiveness?
7
Equivocal Evidence of EffectivenessPivotal Studies
DB#1Dbl-blind (DB)Randomized
PBO ControlledDose Titration
N=75P<0.051
(withdrawal)
DB#2Dbl-blind (DB)Randomized
PBO ControlledDose Withdrawal
N=30P>0.051
Agency at this point can ask for moreevidence (one or more studies)
OR
Investigate further across the clinicaltrial database whether there is a consistent signal of effectiveness or not
1change in score at the end of study
8
Equivocal Evidence of EffectivenessPivotal + Other Studies
OL-1Open label (OL)
WithdrawalDose Titration
N=75
OL-2Open label (OL)
Continue ‘old’ doseN=30
DB#1Dbl-blind (DB)Randomized
PBO ControlledDose Titration
N=75P<0.05
(withdrawal)
DB#2Dbl-blind (DB)Randomized
PBO ControlledDose Withdrawal
N=30P>0.05
9
Significant Dose-Response Relationship – DB1, OL1
Parameter Mean (Confidence Interval)
Between-Patient Variability (CI)
Slope of dose-response, % per mg
4.3*(3.7, 4.6)
56%(46%, 66%)
Within-PatientVariability
26% (23%, 29%)
Estimate of dose-response slope is similar for individual and combinedanalyses. Results from combined shown here.
Linear mixed effects model employed
* p<0.001
10
Significant and Consistent Drug Effects Across Studies
11
Drug in OL1 beat Placebo in DB1 Cross-over comparison
12
Value of Exploratory Analysis
• To Patients/FDA– Availability of drug sooner, especially given no
approved treatments (debilitating disease)– Efficient solution to challenging patient enrollment– Fewer review cycles (because of this issue alone)– Ultimately might lead to lower drug costs
• To Sponsor– Alleviated the need for additional trial(s) to
demonstrate effectiveness– Save $$ and time
• Pharmacometrics analyses can and do influence approval decisions!
13
Why did the sponsor not consider making a similar case?
• Unanticipated concern
• Lack of expertise (both technical, strategic)
• Prescriptive behavior on analysis
• Unclear expectations from FDA
Unlikely
Unlikely
LikelyLikely
14
Parkinson’s DiseaseCollaboration between Statistics
and Pharmacometrics
Dr. Bhattaram and Dr. Siddiqui are the project leads with the following team members:
FDAStatistics, Clinical, Policy Makers
ExternalStatistician, Disease experts
15
Symptomatic or Protective?
Placebo
Drug A
Drug B
16
Symptomatic or Protective?
Placebo
Drug A
Drug B
17
Discern Symptomatic vs. Protective Effects: Delayed Start Design
If drug is protective then patients who received drug longer will havelower scores compared those who receive drug late.
Placebo
Drug
DrugProtective
Placebo Phase Active Phase
Key Questions:-Endpoint ?-Analysis ?-Handling missing data?
18
Parkinson’s Disease Database
Data Source #Patients Trial Duration
Trial#1 NDA 400 1yr + 3yr follow-up
Trial#2 NIH 400 1yr + follow-up
Trial#3 NDA 900 9mo + follow-up
Trial#4 NDA 200 9mo + follow-up
Trial#5 IND 300 1.5yr
19
Published DataMean (SD) of Total UPDRS scores for patients with Parkinson’s disease treated with levodopa alone or in combination with selegiline for 5 years and during the one-month washout period
The vertical line represents 2 months
Selegiline ( 5 years)
Eur.J.Neurology, 1999, 6: 539-547
20
Fra
ctio
n R
emai
ning
Patients with slower progression remain longer in clinical trials (TEMPO)
21
Value of Collaboration between Pharmacometrician, Statistician
• Statistician’s Contribution– Primary statistical analysis
• Drop-outs
– Trial design– Power calculations
• Pharmacometrician’s/Disease Expert’s Contribution– Biological/Mechanistic Interpretation
• Disease Progression• Drug Effects• Drop-outs
– Trial design, alternative analysis
22
Value of Exploratory Analyses• Collected a large database of clinical trials
• Extracted patient population, placebo/disease progression, drug effect (not shown) and drop-out information.
• Simulations to answer the key questions mentioned earlier are in progress– Directly useful to advice sponsors
• Conference planning is underway Disease Models Background: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4248B1-04-FDA-topic%203%20replacement.pdf
23
Take Home Message• Exploratory (e.g., pharmacometric) analyses
are often used to make regulatory decisions– Decisions are not entirely driven by the pre-specified
statistical analysis
• Need for change– Integrate strengths of both approaches
• Think “How exploratory analyses can help drug development?”
– Opportunities for collaboration between pharmacometricians and statisticians are abundant
• Think about “How can I facilitate this collaboration?”
24
top related